Septerna announces novel gpcr-targeted program acquired by vertex

South san francisco, calif.--(business wire)--septerna, a biotechnology company discovering and advancing novel oral small molecule medicines targeting g protein-coupled receptors (gpcrs), today announced that it has signed a definitive asset purchase agreement with vertex pharmaceuticals incorporated (nasdaq: vrtx) under which vertex has acquired an undisclosed discovery-stage gpcr program. under the terms of the agreement, vertex will be responsible for continuing the research and development.
VRTX Ratings Summary
VRTX Quant Ranking